Clinical trials: Lung Cancer Stage I
Lung Cancer
Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
- Trial name
- NCT00990873
- Testing
- gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery.
- Conditions
- Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
- Trial name
- NCT03433469
- Testing
- Osimertinib, Therapeutic Conventional Surgery
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Lung Cancer
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00098462
- Testing
- gefitinib, sirolimus
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Cancer, Endometrial Cancer
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT00315861
- Testing
- pemetrexed, topotecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab
- Conditions
- Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
- Trial name
- NCT04040361
- Testing
- Pembrolizumab, Ramucirumab, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Masahiro Tsuboi
Mesothelioma, Pleural Mesothelioma
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
- Conditions
- Mesothelioma, Pleural Mesothelioma, Wilms Tumor
- Trial name
- NCT04040231
- Testing
- Galinpepimut-S, Nivolumab, Sargramostim
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Gefitinib and everolimus may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving gefitinib together with everolimus may kill more tumor cells.
- Trial name
- NCT00096486
- Testing
- everolimus, gefitinib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer Metastatic
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT…
- Trial name
- NCT01935154
- Testing
- Vx-001
- Where
- 70 sites in Czechia, France and 6 more
- Volunteers
- 221 people
- Sponsor
- Vaxon Biotech
Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
SCION: SABR and Checkpoint Inhibition of NSCLC
The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer. The purpose of the trial is to investigate whether it is safe and effective to combine standard radiation treatment with a drug called…
- Conditions
- Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer Stage I, Lung Cancer
- Trial name
- SCION (NCT04944173)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Circulating Tumor DNA assay
- Where
- 5 sites in Canada
- Sponsor
- University of British Columbia
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8
- Trial name
- NCT04158141
- Testing
- Carboplatin, Cisplatin, Decortication
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- NRG Oncology
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer.
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
- Trial name
- NCT02402920
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Study to determine the maximum tolerated dose (MTD) and safety profile of a single-dose administration of sibrotuzumab (50 mg) conjugated to an increasing dose of 131 I isotope.
- Trial name
- NCT02209727
- Testing
- 131I-Sibrotuzumab
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Resectable NSCLC, KRAS G12C Mutation
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung…
- Conditions
- Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
- Trial name
- K-NADIR (NCT07492342)
- Testing
- fulzerasib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Jianxing He
EGFR Gene Mutation, Nonsmall Cell Lung Cancer
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This is a study for patients with advanced non-small cell lung cancer with changes to their cancer cells called EGFR mutations. Mutated EGFR is important in the growth of cancer cells.
- Trial name
- NCT02954523
- Testing
- Dasatinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Chul Kim
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Non-small Cell Lung Cancer
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
The safety, tolerability, efficacy and pharmacokinetics of ASA404 when administered in combination with paclitaxel and Carboplatin are assessed.
- Trial name
- NCT00674102
- Testing
- ASA404
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01746251
- Testing
- Afatinib
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- Massachusetts General Hospital
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC